Grail plans to submit updated Galleri blood test for FDA approval next year
Grail reported it collected positive initial findings from the latest large study of its multi-cancer early detection test, Galleri, with data the company said it will submit to the FDA as it seeks a full marketing approval.
Grail reported it collected positive initial findings from the latest large study of its multi-cancer early detection test, Galleri, with data the company said it will submit to the FDA as it seeks a full marketing approval.
